CRSP - Here's How the Genetic Testing Industry Can Get Even Bigger
Are you excited about the potential of cutting-edge companies like CRISPR Therapeutics (NASDAQ: CRSP) , Fulgent Genetics (NASDAQ: FLGT) , or Invitae Corp. (NYSE: NVTA) ? You're not alone. The genetic testing market is expected to expand at a compound annual growth rate (CAGR) of 10.1% between 2020 and 2027 and reach over $21 billion in value, according to a report from Allied Market Research.
Ruby Gadelrab is CEO and Founder of MDisrupt, a platform that connects digital health companies to the scientists and healthcare industry experts they need to build, commercialize, and scale health products quickly and responsibly. Ruby joined Olivia Zitkus and Corinne Cardina of Fool.com's Healthcare and Cannabis Bureau on a Jan. 22 episode of Fool Live to talk about the hard work behind every genetic testing company, and what investors need to know about the future of genetic testing in healthcare.
For further details see:
Here's How the Genetic Testing Industry Can Get Even Bigger